about
Pricing and Reimbursement of Biosimilars in Central and Eastern European CountriesThe effectiveness of daily SMS reminders in pharmaceutical care of older adults on improving patients' adherence to antihypertensive medication (SPPA): study protocol for a randomized controlled trialFactors Influencing Non-Persistence with Antiplatelet Medications in Elderly Patients After Ischaemic Stroke.Age-Related Differences in Non-Persistence with Statin Treatment in Patients after a Transient Ischaemic Attack.Patient-related characteristics associated with non-persistence with statin therapy in elderly patients following an ischemic stroke.Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries.Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer.Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA.Non-persistence with antiplatelet therapy in elderly patients after a transient ischemic attack.Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts.Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European CountriesReimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European CountriesHow Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia.Patient-Associated Characteristics Influencing the Risk for Non-Persistence with Statins in Older Patients with Peripheral Arterial Disease
P50
Q33775526-98A8F515-E397-493B-B5F4-9CB3C23B4C0FQ33916917-7F3094AD-C1E9-413D-ACDC-7C2B0F101C07Q39882538-25F0AE85-3D0C-4B87-BE76-48A0CA822851Q47672435-32142125-6CFE-432A-842B-FCF6869B3CB9Q48400944-465990D6-3223-4555-BD4C-8F3C01244457Q48505941-65534538-A405-4655-976A-E086AC10FF07Q49420123-31299210-04F1-4B79-B204-D39DBEFD0717Q49733211-ADDF0DA0-4F01-4DD8-8455-885B26FE05FAQ50654195-C05CC9C5-5F93-4A3E-9759-B3FAF86872EFQ51836249-284E0D74-C52C-41E4-8F1D-BDE7F0D08A44Q55212098-A72BCD6A-7B6D-4553-B7A3-58FEC89F5A4DQ64043899-DA5A8E3D-9973-4549-9624-340A3583F6A9Q64257491-FA4E0BD3-E438-41EF-82BF-4EB4BC76DA77Q64965687-D044B262-EEF6-47A8-8D3D-D58F057354C7Q93133536-C0C71DC8-0DB6-468E-9298-9E2284DEF510
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Tomas Tesar
@ast
Tomas Tesar
@en
Tomas Tesar
@es
Tomas Tesar
@nl
type
label
Tomas Tesar
@ast
Tomas Tesar
@en
Tomas Tesar
@es
Tomas Tesar
@nl
prefLabel
Tomas Tesar
@ast
Tomas Tesar
@en
Tomas Tesar
@es
Tomas Tesar
@nl
P106
P1153
6602516655
P21
P31
P496
0000-0002-0023-4574